Machine Learning

Genmab discontinues its 'encouraging' lung cancer drug, acasunlimab, in a bold strategic pivot to accelerate its most promising late-stage assets.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

The investment firm sheds its medical focus, adopting a new name and a broader mandate to chase cross-sector opportunities in the booming AI market.

A pivotal trial for an acute myeloid leukemia drug is delayed for a promising reason: patients are surviving longer than anticipated, fueling cautious optimism.

Israeli innovator Foresight gets a major nod from Audi, showcasing its all-weather 3D vision system that could redefine autonomous vehicle safety.

A new toothbrush using safe microcurrents claims to remove 6x more plaque and cut gum inflammation. Does the science behind this oral care revolution hold up?

With promising new drugs for obesity and liver disease, clinical-stage MetaVia steps into the spotlight at a key industry conference, facing giants and high hopes.

With a promising schizophrenia drug stalled by FDA requirements and finances tight, Reviva Pharmaceuticals' upcoming presentation is more than just a talk.

iQSTEL caps a transformational year with a NASDAQ uplist, record revenue, and a strategic pivot to Fintech and Cybersecurity, eyeing a $1B future.

Semiconductor metrology leader Nova adds seasoned investor Rami Hadar to its board, signaling a strategic push to accelerate growth and innovation.

MySize Inc. projects a pivotal 2026 after a strategic overhaul, but a history of losses and a plummeting stock price fuel deep market skepticism.

Core AI divests its cash-burning Siyata Mobile hardware unit just months after merging, betting its future entirely on AI-powered gaming and content.

A Korean AI startup raised $854K for a gesture-control ring, betting its enterprise-grade tech can unlock the future of post-touch computing.

Early data shows QurAlis' QRL-101 successfully engaged its intended target in ALS patients, a key step for a novel drug aimed at quelling neuronal storm.

Bluejay Diagnostics can now make 9 million sepsis tests. This manufacturing win is huge, but the real race for FDA approval has only just begun.

A deepened strategic alliance sees mobility tech provider ECARX invest in Lotus, aiming to accelerate the future of the intelligent, AI-driven cockpit.

Crypto exchange Ourbit concludes a massive campaign, leveraging gamification and an NFT with a buyback guarantee to drive $2.2B in volume and redefine loyalty.

Greenwich LifeSciences execs extend their stock lock-up to 6 years, signaling massive confidence in their breast cancer drug showing an 80% recurrence drop.

With a massive IDR 200 billion capital boost from LDA Capital, Indonesian tech firm NANO is set to execute nearly IDR 5 trillion in contracts.

Adlai Nortye licenses its promising pan-RAS cancer inhibitor to ASK Pharm for Greater China in a deal valued at up to $230 million.